In short, our results highlight that age at onset of symptoms, duration of PD and treatment, and LD dosage are factors that may influence the occurrence of dyskinesia, but the variants investigated here may not be involved with this adverse effect, suggesting that studies in larger cohorts with the same variants, particularly rs6935164, should be conducted to reinforce our findings, but also that other genetic factors of PRKN and mitophagy in general may play a role in LID in patients with PD. Here, PRKN is linked to drug-induced dyskinesia.